MTOR and prostate carcinoma: Wu et al have demonstrated that mTOR inhibitor CCI-779 (temsirolimus) can sensitize prostate cancer cells to docetaxel [11], while Morgan et al have shown that RAD001 and docetaxel produce synergy in blocking formation of prostate bone metastases [18].